| Metabolic modulation and optimization of energy consumption in heart failure. | |
| | |
MedLine Citation:
|
PMID: 12693736 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chronic heart failure (CHF) is a common and disabling syndrome with a poor prognosis. It is a major and increasing public health problem. Angiotensin-converting enzyme inhibitors, diuretics, and digitalis are the standards treatments for CHF. Other drugs, such as beta-blockers, spironolactone, calcium antagonists, vasodilators, and antiarrhythmic agents are used to counteract the progression of the syndrome or to improve the hemodynamic profile. Despite optimum treatment with neurohumoral antagonists, prognosis of CHF remains poor; the patients complain of persistent reductions in their exercise capacity and quality of life. Fatigue and shortness of breath, two common and disabling symptoms in patient with CHF, are relatively independent from hemodynamic and neuroendocrine changes, although they seem to be related to the impairment of peripheral muscle metabolism and energetic phosphate production. Therefore, CHF is a complex metabolic syndrome in which the metabolism of cardiac and peripheral muscles is impaired and novel therapeutic strategies have been aimed at positive modulation with compounds such as carnitine, trimetazidine, and ranolazine. |
| | |
Authors:
|
R Ferrari; G Cicchitelli; E Merli; I Andreadou; G Guardigli |
Related Documents
:
|
8783676 - Catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide at... 7521476 - Chronic versus acute effects of amiodarone on the vmax-conduction velocity relationship... 10439886 - Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart fail... 7503006 - Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of... 11641376 - Maturational changes in extracellular matrix and lung tissue mechanics. 15951056 - Exercise energy expenditure is not consciously detected due to oro-gastric, not metabol... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Medical clinics of North America Volume: 87 ISSN: 0025-7125 ISO Abbreviation: Med. Clin. North Am. Publication Date: 2003 Mar |
Date Detail:
|
Created Date: 2003-04-15 Completed Date: 2003-04-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 2985236R Medline TA: Med Clin North Am Country: United States |
Other Details:
|
Languages: eng Pagination: 493-507, xii-xiii Citation Subset: AIM; IM |
Affiliation:
|
Dipartimento di Cardiologia, Università di Ferrara, Arcispedale Sant'Anna, Ferrara, Italy. fri@dns.unife.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetanilides Cardiac Pacing, Artificial Cardiotonic Agents / pharmacology*, therapeutic use* Carnitine / analogs & derivatives*, metabolism*, pharmacology*, therapeutic use* Energy Metabolism Heart Failure / drug therapy*, metabolism*, therapy Humans Piperazines / pharmacology, therapeutic use Trimetazidine / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Acetanilides; 0/Cardiotonic Agents; 0/Piperazines; 110445-25-5/ranolazine; 17298-37-2/propionylcarnitine; 5011-34-7/Trimetazidine; 541-15-1/Carnitine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics.
Next Document: Electrophysiological aids in congestive heart failure: supporting and synchronizing systole.